LAWRENCEVILLE, N.J., Nov. 12, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the third quarter ended September 30, 2013 and provided an update from its retrospective analysis of the clinical trial results for ThermoDox(R), Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin.
Help employers find you! Check out all the jobs and post your resume.
